{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prescribing%2C+Off-Label&page=2",
    "query": {
      "condition": "Prescribing, Off-Label",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prescribing%2C+Off-Label&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T05:51:10.014Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04884763",
      "title": "Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Temporomandibular Disorder"
      ],
      "interventions": [
        {
          "name": "Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments",
          "type": "DRUG"
        },
        {
          "name": "Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-11-15",
      "completion_date": "2024-01-04",
      "has_results": true,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04884763"
    },
    {
      "nct_id": "NCT02748616",
      "title": "C. Difficile and Ursodiol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Ursodiol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2017-03-01",
      "completion_date": "2020-01-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748616"
    },
    {
      "nct_id": "NCT04918914",
      "title": "Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Hypoxia",
        "ARDS"
      ],
      "interventions": [
        {
          "name": "Dapsone 100 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hunt Regional Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-10-18",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Greenville, Texas",
      "locations": [
        {
          "city": "Greenville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04918914"
    },
    {
      "nct_id": "NCT06006143",
      "title": "Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder",
        "Hiv",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-06-16",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06006143"
    },
    {
      "nct_id": "NCT07521371",
      "title": "Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autism Spectrum Disorder",
        "Autism Spectrum Disorder (ASD)",
        "Autism Spectrum Disorder High-Functioning",
        "Autism Spectrum Disorder With Absence of Functional Language",
        "Autism Spectrum Disorder With Impaired Functional Language",
        "Autistic Disorder of Childhood Onset With Full Syndrome",
        "Autistic Disorders Spectrum",
        "Autistic Disorder",
        "Autistic Disorder in Children and Adolescents",
        "Neurodevelopmental Disorders",
        "Neurodevelopmental Disorders (NDD)",
        "Neurodevelopmental Disorders and Developmental Abnormalities"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Healing Hope International",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "4 Years to 21 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-06-01",
      "completion_date": "2030-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Spring, Texas",
      "locations": [
        {
          "city": "Spring",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07521371"
    },
    {
      "nct_id": "NCT07754292",
      "title": "Off-Label Treatment With Immune Checkpoint Inhibitor Blockade",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignancy"
      ],
      "interventions": [
        {
          "name": "One or more off-label ICIs alone or with other on-label ICI(s)",
          "type": "DRUG"
        },
        {
          "name": "Off-label ICI(s) with targeted therapy",
          "type": "DRUG"
        },
        {
          "name": "off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 231,
      "start_date": "2026-11-01",
      "completion_date": "2036-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07754292"
    },
    {
      "nct_id": "NCT07215988",
      "title": "Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a \"Filter\" Observational Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Locally Advanced Basal Cell Carcinoma",
        "Locally Advanced Malignant Skin Neoplasm",
        "Locally Advanced Merkel Cell Carcinoma",
        "Locally Advanced Mucosal Melanoma",
        "Locally Advanced Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Non-Interventional Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2026-02-04",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07215988"
    },
    {
      "nct_id": "NCT00419380",
      "title": "Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Otitis Media"
      ],
      "interventions": [
        {
          "name": "dornase alfa (Pulmozyme®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 41,
      "start_date": "2007-01",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00419380"
    },
    {
      "nct_id": "NCT07806149",
      "title": "NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertrophic Cardiomyopathy",
        "Left Ventricular Outflow Obstruction",
        "Systolic Anterior Motion"
      ],
      "interventions": [
        {
          "name": "SESAME Procedure",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "21 Years to 100 Years"
      },
      "enrollment_count": 200,
      "start_date": "2026-09-27",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 8,
      "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Roslyn",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07806149"
    },
    {
      "nct_id": "NCT03726996",
      "title": "Desipramine in Infantile Neuroaxonal Dystrophy (INAD).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infantile Neuroaxonal Dystrophy"
      ],
      "interventions": [
        {
          "name": "Desipramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 4,
      "start_date": "2019-01-14",
      "completion_date": "2019-08-30",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-09-23T05:51:10.014Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03726996"
    }
  ]
}